Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 9;9(17):4500-4501.
doi: 10.1182/bloodadvances.2025016943.

Reality bites: allocating gene therapy for hemoglobinopathies

Venée N Tubman  1 , Titilope A Fasipe  1
Affiliations
Editorial

Reality bites: allocating gene therapy for hemoglobinopathies

Venée N Tubman et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: V.N.T. and T.A.F. have no competing financial interests relevant to this article.

Comment on

References

    1. Kelkar AH, Achebe MO, Hantel A. An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent beta-thalassemia. Blood Adv. 2025;9(17):4502–4512. - PubMed
    1. Kanter J, Thompson AA, Pierciey FJ, Jr., et al. Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023;98(1):11–22. - PMC - PubMed
    1. Frangoul H, Locatelli F, Sharma A, et al. CLIMB SCD-121 Study Group Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649–1662. - PubMed
    1. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-β0/β0 genotype β-thalassemia. N Engl J Med. 2022;386(5):415–427. - PubMed
    1. Kwiatkowski JL, Walters MC, Hongeng S, et al. Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype beta-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet. 2024;404(10468):2175–2186. - PubMed